Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
about
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSAReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsMechanisms of drug resistance: daptomycin resistanceCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciPotential role of tedizolid phosphate in the treatment of acute bacterial skin infectionsCyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteriaNovel formulations for antimicrobial peptidesTreatment of Gram-positive infections in critically ill patientsOrigin and proliferation of multiple-drug resistance in bacterial pathogensPotential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusAntimicrobial Activity of Cationic Antimicrobial Peptides against Gram-Positives: Current Progress Made in Understanding the Mode of Action and the Response of BacteriaPrevalence of veterinary antibiotics and antibiotic-resistant Escherichia coli in the surface water of a livestock production region in northern ChinaStrain Dependent Genetic Networks for Antibiotic-Sensitivity in a Bacterial Pathogen with a Large Pan-GenomeA mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.Tuning the properties of the bacterial membrane with aminoacylated phosphatidylglycerol.Looking toward basic science for potential drug discovery targets against community-associated MRSAExploring innate glycopeptide resistance mechanisms in Staphylococcus aureusOutcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.Host-guest chemistry of the peptidoglycanCell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanismsExposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureusFirst case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycinModulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.Molecular typing and phenotype characterization of methicillin-resistant Staphylococcus aureus isolates from blood in TaiwanClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteinsCarotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.The evolutionary history of amino acid variations mediating increased resistance of S. aureus identifies reversion mutations in metabolic regulatorsTracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.Mechanisms of antibiotic resistance in Staphylococcus aureus.Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates.Chitosan augments photodynamic inactivation of gram-positive and gram-negative bacteriaComparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure.Genetics of antimicrobial resistance in Staphylococcus aureus.In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approachCorrelation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.
P2860
Q22305769-074097EB-0CAA-4657-8319-9535E6B1B1C4Q24646677-EFD8B0BD-B5B0-4920-B26D-45EA432F45ACQ26779944-5DA25B7D-C720-41DA-A117-204F42ED75A9Q26853465-5DB36935-BEE0-405D-8C7E-905ECB2712C5Q26853612-30A5044B-970F-4620-938E-27B8D5C7A1E0Q26863225-DF152C24-9FEC-498A-9CC8-A5C35F995CBCQ26991771-958571AF-EAD8-4D11-8A38-4CFA91B93F8AQ27015976-7DD6737C-558F-4C83-AB0C-C65437FE450BQ27023284-C29DE7FD-08A6-4260-9760-647E431BBDE9Q27027412-E8F7FD1E-8D00-46C0-8CD8-439E8C381E64Q28072687-31096B46-F7CD-44A2-9DB1-E9BA453EEB48Q28544729-BC1E2C6F-0733-4CA4-BA48-3A4DFB75E587Q28553946-E967674D-8100-4423-BBA7-E7C6D34BCC8CQ30455758-3BACB11B-3B52-4CBE-B7AE-6C0DF48EA4F6Q31131146-4586C0BA-EACC-4544-924B-B97A53D1877DQ33507347-F76BCF5F-24FE-48DB-B7D5-C2D590927584Q33560722-2161EF98-6623-43B9-8A59-037C5517EE3DQ33762805-CF2E38B0-150D-48EF-A691-D1D4CF681198Q33997671-8D74B01B-80CE-4CAC-B6D7-C353F5D0286DQ34013593-5A04869A-01AA-49DA-9C9D-3702A561D92DQ34045376-70428D0C-5CC2-4C49-95E5-6823D038F216Q34057324-D58EE183-B1CD-46E3-9600-7CCD1E836007Q34116509-FC2F8F14-910A-4020-9466-AC7B112EA13FQ34130471-48097A3A-14EB-4B12-961B-72AA7E8F7B47Q34146036-A1DE384A-70A6-44C2-9B1E-2B3C3FC78D75Q34157657-3CDA733A-DF11-4712-AE2C-05E5A13CB7AAQ34278802-553AC3FF-C7CB-4B45-8613-7C89493A36B2Q34529075-CD28E11B-6FE4-49DE-B2FF-CCF320B78CFDQ34592835-9AD6E19B-0432-4842-B5C4-BF4A42968D3DQ34630593-8BB3C863-0236-4069-AF0E-9328ADD87AC0Q34657311-168F5BF2-63E9-4C41-AF88-33FAFF6F1937Q34779009-6F33196A-F234-4FF2-B042-EFC6132A137BQ34932454-D06B5A46-5528-42DD-87FE-6EC57129FF4DQ34932588-7C051E4E-6564-4683-BBE5-B75ED9821D6BQ34984662-D25C1606-C80D-401A-94F6-7D774100D291Q35023234-31788A03-D5D4-4F61-A14D-7FC96AD188ADQ35096905-DA98EC97-AD09-4D49-A788-6FE161C80179Q35139449-12DD3B22-5930-4152-B97F-C989F50E4FDCQ35191417-1D22E514-6870-4F78-92F7-656C06C74C10Q35191555-BEA22012-C3C4-4DEE-AAD0-6E39C0B8F32A
P2860
Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Correlation between Reduced Da ...... mediate Staphylococcus aureus.
@en
Correlation between Reduced Da ...... mediate Staphylococcus aureus.
@nl
type
label
Correlation between Reduced Da ...... mediate Staphylococcus aureus.
@en
Correlation between Reduced Da ...... mediate Staphylococcus aureus.
@nl
prefLabel
Correlation between Reduced Da ...... mediate Staphylococcus aureus.
@en
Correlation between Reduced Da ...... mediate Staphylococcus aureus.
@nl
P2093
P2860
P1476
Correlation between Reduced Da ...... rmediate Staphylococcus aureus
@en
P2093
Eiji Tominaga
Keiichi Hiramatsu
Longzhu Cui
P2860
P304
P356
10.1128/AAC.50.3.1079-1082.2006
P407
P50
P577
2006-03-01T00:00:00Z